Top 10 Best-Selling Hematology Drugs to Look Out For in 2025

As hematology continues to evolve with innovative therapies with broader clinical adoption, several blockbuster drugs are leading the charge both in patient outcomes and commercial success. From groundbreaking CAR-T therapies to next-generation BTK and BCL-2 inhibitors, the hematology drug market saw impressive growth in 2024, setting the stage for even greater competition and therapeutic advancement in 2025.

In this blog, we highlight the top 10 best-selling hematology drugs based on 2024 sales data, each of which not only demonstrated strong market performance but also poised to play a pivotal role this year through expanded indications, clinical innovation or market dynamics.

1. Eliquis (apixaban)

Indication(s): Reduce risk of stroke and systemic embolism in non‑valvular atrial fibrillation, treatment of deep‑vein thrombosis (DVT) and pulmonary embolism (PE), prevention of DVT/PE in post‑hip or knee replacement and reduce recurrent clot risk

Manufacturer(s): Bristol Myers Squibb (BMS) and Pfizer

2024 Sales: $20.70 billion

for 2025: In 2024, Eliquis was a top global blockbuster — pulling in around $20.70 billion in revenue with year-over-year sales growth of approximately 7% to 11%. Its consistent uptake across indications, potential affordability through upcoming Medicare pricing negotiations and lack of US generic competition (until ~2026 and even longer until 2031, potentially) have and are predicted to sustain momentum into 2025, fueling robust demand and steady profits for joint developers BMS and Pfizer. In 2025, continued label expansion, volume growth in atrial fibrillation and venous thromboembolism (VTE) prevention, along with resilient pricing dynamics under Medicare negotiations, position Eliquis for further upside, especially as rivals jostle in the oral anticoagulant space. The upcoming Medicare price negotiations may impact pricing and revenues, which may balance out with potential increased demand.

2. Darzalex (daratumumab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj)

Indication(s): Approved for multiple myeloma. Darzalex IV is used alone or in combination (e.g., with bortezomib, lenalidomide, dexamethasone) across newly diagnosed and relapsed/refractory settings. Darzalex Faspro is a subcutaneous formulation, approved in combination regimens for transplant-eligible and ineligible multiple myeloma patients

Manufacturer(s): Genmab and the Janssen Biotech, Inc. subsidiary of Johnson & Johnson

2024 Sales: $11.67 billion

Outlook for 2025: In 2024, Darzalex net global sales hit approximately $11.7 billion, with over half from the US, a near 20 % year-over-year rise, making it J&J’s top‐selling oncology drug. Darzalex’s growth in 2024 was fueled by broader use across multiple myeloma treatment regimens, spanning both frontline and relapsed/refractory settings. The subcutaneous formulation, Darzalex Faspro, further boosted uptake. In August 2024, the FDA approved Darzalex Faspro in combination with bortezomib, lenalidomide and dexamethasone for induction and consolidation therapy in newly diagnosed patients eligible for autologous stem cell transplant. Later that year, J&J also submitted regulatory applications in the US and the European Union (EU) to expand Faspro’s use to high-risk smoldering multiple myeloma. Continued uptake of Faspro in both transplant-eligible and ineligible patients, potential label expansions and resilience amid biosimilar and next-gen ADC competition will drive further growth, and likely protect its leadership despite mounting market pressures.

3. Imbruvica (ibrutinib)

Indication(s): Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), including 17p‑deletion variants, Waldenström’s macroglobulinemia, chronic graft‑versus‑host disease (cGVHD) and previously for mantle‑cell and marginal‑zone lymphomas

Manufacturer(s): AbbVie/Johnson & Johnson                   

2024 Sales: $6.39 billion

Outlook for 2025: Imbruvica generated around $3.35 billion in net global revenues for the full year for AbbVie and about $3.04 billion for J&J — a ~7 % decline versus 2023 — as US demand softened and competition from next‑gen BTK inhibitors intensified. Despite declining sales, Imbruvica still drives solid cash flow and maintains a broad label, continuing uptake in CLL/SLL and cGVHD. Its entrenched position in clinical practice and established real‑world data keep it central to frontline and relapsed regimens. As newer BTK agents like zanubrutinib and acalabrutinib gain traction, Imbruvica’s market share battle will intensify. Additionally, upcoming Medicare pricing negotiations and potential generic entry timelines (in the mid‑2020s) could intensify pricing pressure, making its competitive positioning and cost resilience key to monitor.

4. Xarelto (rivaroxaban)

Indication(s):  Reducing risk of stroke and systemic embolism in non‑valvular atrial fibrillation (NVAF), treating DVT and PE, preventing recurrent clots, prophylaxis post-hip or knee replacement, VTE prevention in hospitalized medical patients and for certain coronary artery disease (CAD)/peripheral artery disease (PAD) thrombotic risk reductions

Manufacturer(s): Bayer/Johnson & Johnson

2024 Sales: $6.14 billion

Outlook for 2025: Sales declined about 15 % to €3.5 billion (~$3.8 billion) from €4.1 billion in 2023 for Bayer, with generic competition and patent expiration eroding revenues, especially in Q4, where the decline hit ~19 %. J&J revenues from Xarelto totalled $2.37 billion in 2024, just slightly up from the prior year’s $2.37 billion. Despite headwinds, Xarelto’s broad label across multiple thrombotic indications continues to drive strong prescription volume globally, and its entrenched position means it remains a revenue anchor as generics roll in. With accelerated patent loss and generic entry in key markets expected this year, monitoring how Bayer/J&J manage pricing, switch rates to generics and potential label expansions or new supportive real-world data will determine how well Xarelto maintains residual market share.

5. Revlimid (lenalidomide)

Indication(s): Multiple myeloma (with dexamethasone, including as maintenance post‑autologous hematopoietic stem-cell transplant), transfusion‑dependent anemia in low-/intermediate‑1‑risk myelodysplastic syndromes (MDS) with chromosome 5q deletion, chronic lymphocytic leukemia (CLL) only in controlled clinical trials

Manufacturer(s): Bristol Myers Squibb

2024 Sales: $5.77 billion

Outlook for 2025: In 2024, Revlimid ranked among the world’s top-selling oncology drugs, generating approximately $5.77 billion in global revenue. Its broad label across myeloma and MDS, oral dosing convenience and entrenched adoption in frontline and maintenance regimens allowed it to remain a strong cash generator despite looming generic competition. With generics already launched in some territories and more expected, 2025 will reveal how pricing erosion and competitive shifts affect Revlimid’s residual revenue, while also spotlighting strategic moves (e.g., novel combo trials or new niche approvals) aimed at sustaining its legacy portfolio contribution.

6. Hemlibra (emicizumab)

Indication(s): Routine prophylaxis to prevent or reduce bleeding episodes in adults and children (including newborns) with hemophilia A, both with and without factor VIII inhibitors

Manufacturer(s): Roche

2024 Sales (USD): $5.11 billion

Outlook for 2025: In 2024, Hemlibra’s achieved global revenues exceeding $5.11 billion, a 9% year-over-year increase, driven by broad adoption and ongoing expansion across major markets. As a first‑in‑class bispecific monoclonal antibody, Hemlibra offers subcutaneous dosing, superior bleed prevention and ease of administration, contributing to shifting standard care for hemophilia A toward prophylactic therapy. Roche also continues to strengthen its market positioning via new delivery kits and geographic rollout. With competitors like Novo Nordisk’s Mim8 looming, Roche’s execution on longer‑term clinical data, expanded geographic coverage and enhanced patient convenience will be pivotal in defending Hemlibra’s franchise and sustaining its growth trajectory into 2025.

7. Jakafi (ruxolitinib)

Indication(s): Intermediate‑ or high‑risk myelofibrosis, polycythemia vera (after hydroxyurea failure), acute graft‑versus‑host disease (GVHD) and chronic GVHD in adults (and pediatric patients 12 years and older)

Manufacturer(s): Incyte (in the US)/Novartis

2024 Sales: $4.73 billion

Outlook for 2025: Jakafi drove approximately $2.8 billion in net revenues for the full year for Incyte, a solid 8 % year‑over‑year increase, with a particularly strong Q4 where sales jumped 11 % (to ~$773 million). It brought in $1.9 billion for Novartis outside the US. Its broad use in both hematologic malignancies and post-transplant complications, coupled with steady payer demand, makes Jakafi a cornerstone JAK‑STAT therapy, delivering consistent growth despite mounting competition. As Jakafi’s US patent exclusivity approaches 2028, key themes will include label expansion (e.g., new GVHD or inflammatory indications), competitive pressure from next-generation JAK inhibitors and how Incyte continues to grow patient demand while navigating pricing reforms. Incyte raised its 2024 sales forecast to $2.74 billion to 2.77 billion, driven by strong uptake in polycythemia vera and GVHD. Jakafi’s JAK‑STAT targeting fills gaps in both chronic blood cancers and post‑transplant complications. Watch for label expansions and revenue pressure post‑2028 patent cliff.

8. Ultomiris (ravulizumab-cwvz)

Indication(s): Paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD)

Manufacturer(s): Alexion/AstraZeneca

2024 Sales: $3.92 billion

Outlook for 2025: Ultomiris, developed by Alexion, AstraZeneca Rare Disease, is poised to be a hematology drug to watch in 2025 based on its strong commercial performance and expanding clinical use in 2024. The drug generated approximately $3.92 billion in global product sales in 2024, reflecting a 12% increase over the previous year. In the first half of 2024 alone, Ultomiris recorded $1.8 billion in sales, representing a 32% year-over-year growth. AstraZeneca also reported that its rare disease portfolio grew by 21% in 2024, with Ultomiris as a key driver of that growth. One of the main reasons Ultomiris stands out is its role in replacing Soliris, AstraZeneca’s earlier complement inhibitor. While Soliris experienced declining revenues due to biosimilar competition and patient transitions, Ultomiris saw robust sales growth, signaling a successful market conversion strategy. Its longer dosing interval (every eight weeks versus every two weeks for Soliris) is another advantage that has likely contributed to increased physician and patient preference.

9. Pomalyst (pomalidomide)

Indication(s): Relapsed or refractory multiple myeloma, AIDS‑related Kaposi sarcoma following highly active antiretroviral therapy (HAART) failure or in HIV‑negative patients

Manufacturer(s): Bristol Myers Squibb

2024 Sales: $3.55 billion

Outlook for 2025: Pomalyst was one of Bristol‑Myers Squibb’s top-performing oncology products in 2024, accounting for around 7.3% of company revenues. Pomalyst’s oral, daily dosing and its efficacy in heavily pre‑treated multiple myeloma have cemented it as a go‑to later‑line therapy. In the US, Pomalyst is a central treatment for relapsed or refractory multiple myeloma. It complements other agents (like daratumumab) in triple‑combination regimens, reinforcing its role in evolving treatment regimens. Market analysts are watching for margin and uptake shifts as generics entered EU markets in August 2024, as well as ongoing patent‑litigation outcomes and potential label extensions or new combination approvals that could prolong its lifecycle and preserve revenue amid increasing competition. In April 2025, a federal judge dismissed a proposed class action against Bristol Myers Squibb, finding insufficient evidence that the company or its subsidiary, Celgene, used fraudulent patents or baseless lawsuits to unlawfully block Pomalyst generics.

10. Soliris (eculizumab)

Indication(s): PNH and aHUS, gMG and NMOSD

Manufacturer(s): Alexion/AstraZeneca

2024 Sales: $2.59 billion

Outlook for 2025: Soliris is a hematology drug to watch in 2025 due to its strong performance in rare blood disorders and a substantial, though declining, revenue base. In 2024, Soliris generated approximately $2.59 billion in global sales, representing an 18% decline from the previous year. This decrease was largely attributed to the transition of patients to its follow-on product, Ultomiris, and the entrance of biosimilar competition. However, despite this decline, the drug’s revenue remains significant, underscoring its enduring role in treating rare and life-threatening conditions such as PNH and aHUS. While biosimilar versions of eculizumab, such as Bkemv and Epysqli, received FDA approval in 2024, Soliris is still forecasted to see sustained demand. One analysis estimates that the Soliris market, despite recent headwinds, could grow from around $4.2 billion in 2024 to over $9.3 billion by 2033.